The emerging properties of mimicking enzymes open up new horizons for nanomaterials. Regulating their enzyme-like activity and exploiting their applications are currently the hot topics for nanozymes. Among their activities, the pro-oxidant and antioxidant capabilities of nanozymes are important to determine their unique physiological functions. In this paper, we demonstrate that PtRu NPs exhibit multiple enzyme-like activities (e.g. peroxidase, oxidase, ferroxidase, catalase and SOD) and 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity. The PtRu bimetallic nanozymes therefore show pro-oxidant and anti-oxidant functions. It was found that the enzyme-like activities of PtRu NPs are highly dependent on the Pt/Ru molar ratio and show a similar trend in the order of activity: Pt₉₀Ru₁₀ > Pt₇₅Ru₂₅ > Pt > Pt₄₀Ru₆₀, indicating that proper alloying of Pt with Ru can enhance both pro- and anti-oxidant capabilities. By employing the ferroxidase-like activity and catalase-like activity, we verified the applications of PtRu nanozymes in the detection of Fe²⁺ ions, and tried for the first time to protect Monascus pigments (MPs) from hydrogen peroxide oxidation. These results not only provide an effective way to optimize the pro- and anti-oxidant capabilities of nanozymes, but also provide prospects for the applications of nanozymes in protecting biologically active natural products.

Henoch-Schönlein purpura nephritis (HSPN) is the most common secondary glomerular disease in children. Currently, the treatment for HSPN is always selected based on the Kidney Disease Improving Global Outcomes guidelines; however, this approach may lead to undertreatment, especially in patients with persistent proteinuria that does not reach nephrotic levels and/or hematuria and those with a pathological classification between grades 1 and 3 according to the International Study of Kidney Disease in Children. This study was performed to evaluate the curative effect and safety of a traditional Chinese medicine (TCM) integrated treatment program in this type of HSPN. This multicenter, open-label, large-sample, randomized controlled trial was performed in China and included 500 children with HSPN exhibiting mild pathological patterns. The treatment group to control group ratio was 2:1, and each group was further stratified into two types, light and heavy, according to urinary protein quantification and pathological type. The treatment group received tripterygium glycosides (TGs), tanshinone IIa sodium sulfonate injection, and Chinese herbs selected based on syndrome differentiation in TCM. The heavy and light subgroups received treatment courses and dosages of TG. In the control groups, the light group received benazepril hydrochloride tablets, low molecular weight heparin calcium injection, dipyridamole tablets, and a Chinese medicine placebo, while the heavy group received the same treatment plus prednisone. All groups were treated for 3 months and then followed up for 9 months. The efficacy and safety of the treatments were then evaluated among the groups. Currently, few treatments are available for HSPN patients with mild pathological patterns indicating light to moderate proteinuria and/or hematuresis. In this large-sample study, we provide a new approach for HSPN that includes an integrated treatment program that incorporates TCM. Clinical Trials.gov, NCT03591471 . Re-registered on 19 July 2018.

Background: It has been demonstrated that ASHMI (antiasthma-simplified herbal medicine intervention) can improve airway function and reduce inflammation in human asthmatic patients with high safety and tolerability. In addition, ASHMI significantly suppresses Th2 cytokine production and increases Th1 cytokine production in treating asthma. Objective: Allergic asthma is associated with dysregulation of cytokines. We focused on IL-5 and IL-10 as signature Th2 and Treg cytokines to characterize ASHMI immunomodulatory components. Methods: The effects of ASHMI and individual herbal constituents on IL-5 and IL-10 production by PBMCs from asthmatic subjects were determined ex vivo. Sophora flavescens (SF)-F2, containing alkaloid compounds, effects on PBMC IL-10 and IL-5 production in the presence or absence of dexamethasone (Dex), and on DNA methylation levels at the foxp3 gene promoter were determined. Results: The ratio of anti-CD3/CD28 stimulated IL-10/IL-5 production by PBMCs from asthmatic subjects was significantly reduced compared to healthy subjects. In PBMCs from asthmatic subjects, ASHMI significantly reduced IL-5 production and increased IL-10 secretion in a dose-dependent manner (p < 0.05– 0.01). SF-F2 was most effective in increasing IL-10, whereas SF-F4 (flavonoid compounds) was most effective in suppressing IL-5 production. Dex-treated PBMCs from asthma subjects showed a trend of increasing ratio of IL-10/IL-5 while demonstrating reduced levels in both IL-5 and IL-10 (p < 0.05). Co-culture with Dex and SF-F2 significantly prevented Dex suppression of IL-10, while retained Dex-suppression of IL-5 production, and increased IL-10/IL-5 ratio by Dex. Co-culture with SF-F2 and Dex significantly reduced DNA methylation levels at the foxp3 gene promoter at CpG^{− 126}. Conclusion: The SF alkaloid-rich fraction may be responsible for ASHMI induction of IL-10 production by PBMCs and plays a synergistic effect with Dex for augmenting IL-10/IL-5 ratio.

Objective: Henoch–Schönlein purpura (HSP) is the most common vasculitis in children. Renal involvement is the main long-term complication of HSP, and presently there is no way to predict which children may have irreversible renal damage from the outset. This study aimed to explore the prediction value of laboratory indexes on renal involvement in children with HSP, which could help the early identification and intervention. Methods: Children with HSP hospitalized at the First Affiliated Hospital of Henan University of Chinese Medicine from June 2019 to December 2020 were included. The demographic findings, clinical features, laboratory findings including blood routine examination, serum immunoglobulin, complement, T cell subsets levels, liver and kidney function, coagulation function were recorded. Laboratory indexes were analyzed, logistic regression analysis was performed to identify the independent predictors in HSP patients with renal involvement, and receiver operating characteristic (ROC) curves were further used to assess the value of prediction indexes, as well as the efficacy of combined diagnosis. Results: The study included 146 HSP patients, among them, 50 patients (34.2%) had renal involvement. Age, platelet distribution width (PDW), CD3⁺ and fibrinogen (FIB) were positively correlated with renal involvement, while the levels of Immunoglobulin G (IgG), C-reactive protein (CRP), and neutrophil/lymphocyte ratio (NLR) were negatively correlated with renal involvement. The area under the ROC Curve (AUC) of these biomarkers ranged from 0.6284 to 0.7009, and among the combinations, a combination of NLR, CRP, CD3⁺, FIB, PDW, IgG and age had the best AUC value (0.9774). Conclusion: Age, PDW, CD3⁺, FIB, CRP, NLR and IgG were prediction indexes for renal involvement in HSP patients, and these indexes can be combined appropriately to improve the diagnostic efficacy.

Acute kidney injury (AKI) is a complex syndrome with multiple causes, associated with high morbidity and mortality rates. Despite advances in intensive care, effective therapeutic strategies for AKI remain limited. In this review, we examine the roles of oxidative stress and endoplasmic reticulum stress (ERS) in the pathogenesis of AKI. Oxidative stress, marked by the excessive production of reactive oxygen species (ROS), can trigger ERS, leading to misfolded protein accumulation and activation of the unfolded protein response (UPR) in an attempt to restore cellular homeostasis. When ERS becomes prolonged or excessive, persistent activation of UPR pathways such as IRE1, PERK and ATF6 induces apoptosis and further worsens kidney injury. In addition to apoptosis, oxidative stress and ERS also regulate autophagy, a cellular stress response. Together, these pathways promote cellular dysfunction and advance AKI progression. We also discuss potential therapies that target oxidative stress and ERS, such as antioxidants and pharmacological agents targeting UPR pathways, which may offer promising approaches to mitigate AKI. A deeper understanding of the interplay between oxidative stress and ERS in AKI is essential for developing effective therapeutic interventions to improve patient outcomes.